Table 1: Studies correlating immunobiomarkers with clinical results.

StudyN (patients)Immune biomarkerResults

Balsari et al. [21] DCIS: 62
Invasive: 257
Normal breast: 10
FOXP3High FOXP3 in invasive and in situ breast carcinoma than in normal breast
High FOXP3 shorter PFS and OS
Negative correlation between FOXP3 and ER
Ladoire et al. [4] 56CD3
CD8
FOXP3
Poor prognostic factors (RE−, high-tumor grade and nodal involvement) correlate with higher number of FOXP3 before chemotherapy
>pCR to neoadjuvant chemotherapy correlates with absence of FOXP3 cells and presence of high number of CD8 T cell
Bates et al. [20] 183 + 214FOXP3FOXP3 expression in tumor associated with worse overall survival
FOXP3 prognostic factor for distant metastases free survival
Demaria et al. [1] 25TILDevelopment of TIL after treatment correlates with clinical response to neoadjuvant chemotherapy
Denkert et al. [2] 1058 (2 cohort)TILHigh TILs: pCR rates 42 and 40% versus 3 and 7%
Perez et al. [5] 24 normal breast
74 breast cancer (28 HER−; 46 HER+)
TregsTreg frecuency in HER2+ was significantly increased.
Trastuzumab therapy: decreased Treg frecuency/objective clinical response
Mahmoud et al. [6] 1334 CD8+ TTIL CD8+ density associated with improved clinical outcome

PFS: progression free survival; OS: overall survival; ER: estrogen receptor; and pCR: pathologic complete response.